Angelicin impedes the progression of glioblastoma via inactivation of YAP signaling pathway
Glioblastoma (GBM) is a human malignant tumor with low survival and high recurrence rate. Angelicin, an active furanocoumarin compound, has been reported to possess potential antitumor activity towards various malignancies. However, the effect of angelicin on GBM cells and its mechanism are still un...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-05-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332223002500 |
_version_ | 1797857725688840192 |
---|---|
author | Mengmeng Wang Shuqiao Xing Jiamei Jia Weiquan Zeng Jia Lei Yiming Qian Zhenrong Xiong Xin Wang Liying Cao Yongjie Wang Ying Wang Yuanyuan Jiang Zhihui Huang |
author_facet | Mengmeng Wang Shuqiao Xing Jiamei Jia Weiquan Zeng Jia Lei Yiming Qian Zhenrong Xiong Xin Wang Liying Cao Yongjie Wang Ying Wang Yuanyuan Jiang Zhihui Huang |
author_sort | Mengmeng Wang |
collection | DOAJ |
description | Glioblastoma (GBM) is a human malignant tumor with low survival and high recurrence rate. Angelicin, an active furanocoumarin compound, has been reported to possess potential antitumor activity towards various malignancies. However, the effect of angelicin on GBM cells and its mechanism are still unclear. In this study, we found that angelicin inhibited the proliferation of GBM by inducing the cell cycle arrested in G1 phase and suppressed the migration of GBM cells in vitro. Mechanically, we found that angelicin downregulated the expression of YAP and decreased the nuclear localization of YAP, and suppressed the expression of β-catenin. Furthermore, overexpression of YAP partially restored the inhibitory effect of angelicin on GBM cells in vitro. Finally, we found that angelicin could inhibit the growth of tumor and reduce the expression of YAP in the subcutaneous xenograft model of GBM in nude mice and the syngeneic intracranial orthotopic model of GBM in C57BL/6 mice. Taken together, our results suggest that the natural product angelicin exerts its anticancer effects on GBM via YAP signaling pathway, and is expected to be a promising compound for the treatment of GBM. |
first_indexed | 2024-04-09T21:02:31Z |
format | Article |
id | doaj.art-fe9ac1ce0c08426c90b3f381f1abde7a |
institution | Directory Open Access Journal |
issn | 0753-3322 |
language | English |
last_indexed | 2024-04-09T21:02:31Z |
publishDate | 2023-05-01 |
publisher | Elsevier |
record_format | Article |
series | Biomedicine & Pharmacotherapy |
spelling | doaj.art-fe9ac1ce0c08426c90b3f381f1abde7a2023-03-29T09:22:26ZengElsevierBiomedicine & Pharmacotherapy0753-33222023-05-01161114462Angelicin impedes the progression of glioblastoma via inactivation of YAP signaling pathwayMengmeng Wang0Shuqiao Xing1Jiamei Jia2Weiquan Zeng3Jia Lei4Yiming Qian5Zhenrong Xiong6Xin Wang7Liying Cao8Yongjie Wang9Ying Wang10Yuanyuan Jiang11Zhihui Huang12School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, Zhejiang 311121, ChinaSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, Zhejiang 311121, ChinaSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, Zhejiang 311121, ChinaSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, Zhejiang 311121, ChinaSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, Zhejiang 311121, ChinaSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, Zhejiang 311121, ChinaSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, Zhejiang 311121, ChinaSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, Zhejiang 311121, ChinaSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, Zhejiang 311121, ChinaSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, Zhejiang 311121, ChinaClinical Research Center, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 311121, China; Corresponding author.School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Corresponding authors at: School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Corresponding authors at: School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.Glioblastoma (GBM) is a human malignant tumor with low survival and high recurrence rate. Angelicin, an active furanocoumarin compound, has been reported to possess potential antitumor activity towards various malignancies. However, the effect of angelicin on GBM cells and its mechanism are still unclear. In this study, we found that angelicin inhibited the proliferation of GBM by inducing the cell cycle arrested in G1 phase and suppressed the migration of GBM cells in vitro. Mechanically, we found that angelicin downregulated the expression of YAP and decreased the nuclear localization of YAP, and suppressed the expression of β-catenin. Furthermore, overexpression of YAP partially restored the inhibitory effect of angelicin on GBM cells in vitro. Finally, we found that angelicin could inhibit the growth of tumor and reduce the expression of YAP in the subcutaneous xenograft model of GBM in nude mice and the syngeneic intracranial orthotopic model of GBM in C57BL/6 mice. Taken together, our results suggest that the natural product angelicin exerts its anticancer effects on GBM via YAP signaling pathway, and is expected to be a promising compound for the treatment of GBM.http://www.sciencedirect.com/science/article/pii/S0753332223002500AngelicinGBMYAPProliferationCell cycleMigration |
spellingShingle | Mengmeng Wang Shuqiao Xing Jiamei Jia Weiquan Zeng Jia Lei Yiming Qian Zhenrong Xiong Xin Wang Liying Cao Yongjie Wang Ying Wang Yuanyuan Jiang Zhihui Huang Angelicin impedes the progression of glioblastoma via inactivation of YAP signaling pathway Biomedicine & Pharmacotherapy Angelicin GBM YAP Proliferation Cell cycle Migration |
title | Angelicin impedes the progression of glioblastoma via inactivation of YAP signaling pathway |
title_full | Angelicin impedes the progression of glioblastoma via inactivation of YAP signaling pathway |
title_fullStr | Angelicin impedes the progression of glioblastoma via inactivation of YAP signaling pathway |
title_full_unstemmed | Angelicin impedes the progression of glioblastoma via inactivation of YAP signaling pathway |
title_short | Angelicin impedes the progression of glioblastoma via inactivation of YAP signaling pathway |
title_sort | angelicin impedes the progression of glioblastoma via inactivation of yap signaling pathway |
topic | Angelicin GBM YAP Proliferation Cell cycle Migration |
url | http://www.sciencedirect.com/science/article/pii/S0753332223002500 |
work_keys_str_mv | AT mengmengwang angelicinimpedestheprogressionofglioblastomaviainactivationofyapsignalingpathway AT shuqiaoxing angelicinimpedestheprogressionofglioblastomaviainactivationofyapsignalingpathway AT jiameijia angelicinimpedestheprogressionofglioblastomaviainactivationofyapsignalingpathway AT weiquanzeng angelicinimpedestheprogressionofglioblastomaviainactivationofyapsignalingpathway AT jialei angelicinimpedestheprogressionofglioblastomaviainactivationofyapsignalingpathway AT yimingqian angelicinimpedestheprogressionofglioblastomaviainactivationofyapsignalingpathway AT zhenrongxiong angelicinimpedestheprogressionofglioblastomaviainactivationofyapsignalingpathway AT xinwang angelicinimpedestheprogressionofglioblastomaviainactivationofyapsignalingpathway AT liyingcao angelicinimpedestheprogressionofglioblastomaviainactivationofyapsignalingpathway AT yongjiewang angelicinimpedestheprogressionofglioblastomaviainactivationofyapsignalingpathway AT yingwang angelicinimpedestheprogressionofglioblastomaviainactivationofyapsignalingpathway AT yuanyuanjiang angelicinimpedestheprogressionofglioblastomaviainactivationofyapsignalingpathway AT zhihuihuang angelicinimpedestheprogressionofglioblastomaviainactivationofyapsignalingpathway |